LUMACAFTOR ( DrugBank: Lumacaftor )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	82

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 10 of 82 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04235140 (ClinicalTrials.gov)	February 24, 2020	15/1/2020	Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F50 ...	A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumac ...	Cystic Fibrosis	Drug: LUM/IVA	Vertex Pharmaceuticals Incorporated	NULL	Active, not recruiting	12 Months	N/A	All	52	Phase 3	United States;Canada
2	EUCTR2019-001314-41-NL (EUCTR)	06/05/2019	06/05/2019	This study investigates the effect of switching from Orkambi treatment to Symkevi. In particuar we w ...	Kinetics of ivacaftor at Switch Orkambi Symkevi study - SOS	Cystic fibrosis;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and A ...	Trade Name: Orkambi: contains lumacaftorand ivacaftor Product Name: Orkambi Trade Name: Symkevi Product ...		NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Netherlands
3	NCT03956589 (ClinicalTrials.gov)	October 1, 2018	2/5/2019	Functional Respiratory Imaging and Orkambi in CF	Functional Respiratory Imaging (FRI) to Assess the Short-term Effect of the Product ORKAMBI (Lumacaf ...	Cystic Fibrosis	Drug: Orkambi	University Hospital, Antwerp	NULL	Terminated	12 Years	N/A	All	12	Phase 4	Belgium
4	NCT03601637 (ClinicalTrials.gov)	September 7, 2018	18/7/2018	Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of A ...	A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaf ...	Cystic Fibrosis	Drug: LUM;Drug: IVA	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Months	23 Months	All	61	Phase 3	United States;Canada
5	NCT03625466 (ClinicalTrials.gov)	August 10, 2018	7/8/2018	A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Thro ...	An Exploratory Phase 2, 2-part, Randomized, Double-blind, Placebo-controlled Study With a Long-term, ...	Cystic Fibrosis	Drug: LUM;Drug: IVA;Drug: Matched Placebos	Vertex Pharmaceuticals Incorporated	NULL	Active, not recruiting	2 Years	5 Years	All	51	Phase 2	Germany
6	NCT04732910 (ClinicalTrials.gov)	July 1, 2018	25/1/2021	Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR ...	CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie	Cystic Fibrosis	Drug: Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor ...	Charite University, Berlin, Germany	Hannover Medical School;Heidelberg University;University of Giessen	Recruiting	6 Months	N/A	All	90		Germany
7	NCT03565692 (ClinicalTrials.gov)	July 1, 2018	31/5/2018	Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taki ...	Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taki ...	Cystic Fibrosis	Biological: the lung mycobiota and microbiota profile;Biological: the gut mycobiota and microbiota p ...	University Hospital, Bordeaux	Societe Francaise de la Mucoviscidose	Recruiting	2 Years	N/A	All	250		France
8	EUCTR2017-003761-99-DE (EUCTR)	27/06/2018	19/02/2018	A Study of the Effects of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Y ...	An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, ...	Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;Sy ...	Product Name: lumacaftor/ ivacaftor Product Code: VX-809 / VX-770 INN or Proposed INN: LUMACAFTOR Other ...	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Germany
9	EUCTR2018-001573-24-BE (EUCTR)	11/06/2018	08/05/2018	Evaluation of the short-term effect of ORKAMBI on lung function in patients with cystic fibrosis who ...	Functional Respiratory Imaging (FRI) to assess the short-term effect of the product ORKAMBI (lumacaf ...	Cystic Fibrosis Homozygous (homozygous for the F508del mutation) MedDRA version: 20.0;Level: PT;Clas ...	Trade Name: Orkambi INN or Proposed INN: LUMACAFTOR Other descriptive name: LUMACAFTOR INN or Proposed ...	Antwerp University Hospital	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 4	Belgium
10	NCT02653027 (ClinicalTrials.gov)	January 1, 2018	7/1/2016	Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del	A Study of the Effect of Combination Lumacaftorand Ivacaftor on Glucose Tolerance in Persons With Cy ...	Diabetes;Cystic Fibrosis	Drug: Lumacaftor-ivacaftor;Other: OGTT	Massachusetts General Hospital	NULL	Withdrawn	18 Years	65 Years	All	0	N/A	NULL

First Previous1 2 3 4 5…9Next Last